Pancreatic Cancer Research

ResearcherUniversity of TsukubaActive in the last 2 years

Yoshihiro Miyazaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1851-964X; OpenAlex author ID A5005882584. Sources: OpenAlex.

Their work

Papers
15
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 4 papers · 2024: 2 papers · 2025: 2 papers · 2026: 2 papers

Papers 15

  1. Stromal FAP-targeted 18F-FAPI-74 PET/CT in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2026.07.004↗
  2. Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics. Co-author DOI 10.1038/s41416-026-03577-w↗
  3. Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-02404-1↗
  4. Safety and pathological impact of resection after high-dose PBT for locally advanced pancreatic cancer. Co-author DOI 10.1186/s12957-025-03992-y↗
  5. Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. Co-author DOI 10.1155/2024/1529449↗
  6. Hypoxia at 3D organoid establishment selects essential subclones within heterogenous pancreatic cancer. Co-author DOI 10.3389/fcell.2024.1327772↗
  7. Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer. Co-author DOI 10.1002/ijc.34362↗
  8. Total Superior Mesenteric Artery Nerve Plexus Preservation During Pancreaticoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1007/s00268-023-07111-4↗
  9. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II… Co-author DOI 10.1186/s12885-023-11110-y↗
  10. YAP/BRD4-controlled ROR1 promotes tumor-initiating cells and hyperproliferation in pancreatic cancer. Co-author DOI 10.15252/embj.2022112614↗
  11. Potential Metabolite Markers for Pancreatic Cancer Identified by Metabolomic Analysis of Induced Cancer-Associated Fibroblasts. Co-author DOI 10.3390/cancers14061375↗
  12. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic duc… Co-author DOI 10.1016/j.suronc.2021.101542↗
  13. Carcinoembryonic antigen as a specific glycoprotein ligand of rBC2LCN lectin on pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1111/cas.15023↗
  14. Adipose-derived mesenchymal stem cells differentiate into pancreatic cancer-associated fibroblasts in vitro. Co-author DOI 10.1002/2211-5463.12976↗
  15. Novel Pancreatic Cancer Therapy Targeting Cell Surface Glycans by Liposomes Modified with rBC2LCN Lectin. Co-author DOI 10.1159/000513430↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tatsuya Oda · 15 shared papers, 2020–2026 · strength 2.66
  2. Osamu Shimomura · 12 shared papers, 2020–2026 · strength 2.10
  3. Hiromitsu Nakahashi · 7 shared papers, 2023–2026 · strength 1.47
  4. Yoshimasa Akashi · 8 shared papers, 2021–2026 · strength 1.42
  5. Yukihito Kuroda · 5 shared papers, 2020–2026 · strength 0.89
  6. Tomoaki Furuta · 5 shared papers, 2020–2026 · strength 0.84
  7. Hiroaki Tateno · 5 shared papers, 2020–2025 · strength 0.83
  8. Tsuyoshi Enomoto · 4 shared papers, 2020–2025 · strength 0.63
  9. Takahito Nakajima · 3 shared papers, 2023–2026 · strength 0.54
  10. Shuntaro Tsukamoto · 2 shared papers, 2025–2026 · strength 0.50
  11. Hideyuki Sakurai · 3 shared papers, 2021–2025 · strength 0.43
  12. Haruko Numajiri · 3 shared papers, 2021–2025 · strength 0.43
  13. Koichiro Kumano · 2 shared papers, 2024–2026 · strength 0.42
  14. Yasuyuki S. Kida · 2 shared papers, 2020–2022 · strength 0.36
  15. Masato Endo · 2 shared papers, 2023–2025 · strength 0.32
  16. Kiichiro Tsuchiya · 2 shared papers, 2023–2025 · strength 0.32
  17. Yuichi Hiroshima · 2 shared papers, 2021–2025 · strength 0.30
  18. Yusuke Ohara · 2 shared papers, 2021–2023 · strength 0.27
  19. Kentaro Hatano · 1 shared paper, 2026 · strength 0.25
  20. Sota Kimura · 2 shared papers, 2020–2021 · strength 0.23
  21. Kazuya Yamagata · 1 shared paper, 2023 · strength 0.19
  22. Masaya Yamazaki · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.